Issue Date: January 6, 2014
Jazz Grows Rare Disease Portfolio With Gentium Buy
Jazz Pharmaceuticals will pay roughly $1 billion in cash to acquire Gentium, an Italian biotech firm focused on treating rare diseases. Gentium recently received European regulatory approval for Defitelio, a treatment for a condition in which veins in the liver are blocked in people undergoing a stem cell transplant. Jazz says the purchase complements its oncology and hematology portfolio. The deal is expected to close in the first quarter.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society